S

    Skye Bioscience, Inc. Common Stock (SKYE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.77
    -0.18 (-8.97%)

    Market Cap: $7.86M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(5/11)
    Avg Surprise
    -5.91%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.12
    Range$-1.12 - $-1.12
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-1.79-60.0%
    60d ago$-2.01-79.8%
    30d ago$-2.01-79.8%
    7d ago$-2.01-79.8%
    Current$-1.12
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Dec 31, 2026
    EPS Consensus$-3.33
    Range$-3.33 - $-3.33
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-3.33---
    Sep 26EST
    		-$-1.12---
    Jun 26
    		$-0.27$-0.29+6.90%Beat+38.6%
    Mar 26
    		$-0.32$-0.32+0.00%Beat-14.3%
    Dec 25
    		$-2.95$-2.45-20.20%Miss-912.6%
    Sep 25
    		$-0.32$-0.32+0.00%Beat-220.0%
    Jun 25
    		$-0.44$-0.34-29.41%Miss-120.0%
    Mar 25
    		$-0.28$-0.29+3.45%Beat-55.6%
    Dec 24
    		$-0.29$-0.28-2.18%Miss+53.8%
    Sep 24
    		$-0.10N/A+60.00%Beat+96.8%
    Jun 24
    		$-0.20$-0.19-5.26%Miss-6150.0%
    Mar 24
    		$-0.18$-0.16-12.50%Miss-3172.7%
    Dec 23
    		$-0.63$-0.38-65.79%Miss-6200.0%
    Sep 23
    		$-3.17$0.00N/AMiss-31555.0%
    Jun 23
    		$-0.00$0.00N/AMiss+68.0%
    Mar 23
    		$-0.01$0.00N/AMiss+45.0%
    Dec 22
    		$-0.01$0.00N/AMiss+0.0%
    Sep 22
    		$-0.01$0.00N/AMiss-127.3%
    Jun 22
    		$-0.01N/AN/ABeat+0.0%
    Mar 22
    		$-0.01N/AN/ABeat+0.0%
    Dec 21
    		$-0.01N/AN/ABeat+0.0%
    Sep 21
    		$-0.00N/AN/ABeat+56.0%
    Jun 21
    		$-0.01N/AN/ABeat+0.0%
    Mar 21
    		$-0.01N/AN/ABeat+0.0%
    Dec 20
    		$-0.01N/AN/ABeat-133.3%
    Sep 20
    		$-0.01N/AN/ABeat+75.0%
    Jun 20
    		$-0.01$0.00N/AMiss-112.5%
    Mar 20
    		$-0.01$0.00N/AMiss+90.9%
    Dec 19
    		$0.03$0.00N/ABeat+160.0%
    Sep 19
    		$-0.04$0.00N/AMiss-100.0%
    Jun 19
    		$0.08$0.00N/ABeat+500.0%
    Mar 19
    		$-0.11$0.00N/AMiss-22.2%
    Dec 18
    		$-0.05$0.00N/AMiss-66.7%
    Sep 18
    		$-0.02$0.00N/AMiss+0.0%
    Jun 18
    		$-0.02$0.00N/AMiss+0.0%
    Mar 18
    		$-0.09$0.00N/AMiss-262.9%
    Dec 17
    		$-0.03$0.00N/AMiss+66.7%
    Sep 17
    		$-0.02$0.00N/AMiss+78.8%
    Jun 17
    		$-0.02$0.00N/AMiss-
    Mar 17
    		$-0.02$0.00N/AMiss-
    Dec 16
    		$-0.09$0.00N/AMiss-
    Sep 16
    		$-0.09$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.06EV/EBITDA-2.56x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-233.90%ROIC12418.52%
    Financial Health
    Debt/Equity-0.07xInterest CoverageN/A
    Current Ratio0.95xQuick Ratio0.95x
    Trading Statistics
    Beta2.99Avg Volume1.10M
    52-Week High$4.9952-Week Low$0.26

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.31
    SMA 20$3.30
    SMA 50$4.50
    SMA 200$6.44
    EMA 10$2.40
    EMA 20$3.07
    EMA 50$4.18
    EMA 200$7.82

    MACD

    Line: -0.82Signal: -0.70Hist: -0.12

    ADX

    ADX: 39.5+DI: 4.6-DI: 1.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down80.0
    PSAR$0.42

    Bollinger Bands

    Upper Band$5.48
    Lower Band$1.12
    %B Position13193%(Upper)
    Band Width0.15

    RSI (14-Day)

    Oversold
    15.5

    Momentum Oscillators

    Stoch %K80.4
    Stoch %D84.2
    Williams %R-26.4
    ROC (10d)-55.8%
    Momentum-2.24
    CCI (20d)34.1
    MFI (14d)2.4

    Volatility Measures

    ATR (14d)$2.63(148.2%)
    StdDev (20d)1.09
    Hist Vol114.4%(High)

    Volume Flow

    VWAP$1.83
    OBV5.6M
    AD Line23.9B
    CMF (20d)45.112

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.1x(Low)
    VWMA (20d)$3.34

    Pivot Points

    R3$2.07
    R2$2.04
    R1$2.00
    Pivot Point$1.97
    S1$1.93
    S2$1.90
    S3$1.86

    Advanced Oscillators

    TSI-59.15
    Ultimate Osc88.2
    KST-489.93

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$163,389$0
    Cost of RevenueN/A$172,886$180,009N/A$187,066$177,379$175,293$65,997$29,790$27,560$28,371$28,789
    Gross ProfitN/A$-172,886$-180,009N/A$-187,066$-177,379$-175,293$-65,997$-29,790$-27,560$-28,371$-28,789
    Operating Expenses$11.06M$12.50M$14.90M$13.26M$18.24M$11.76M$10.67M$4.97M$8.41M$6.15M$4.09M$24.71M
    R&D$3.94M$7.76M$11.47M$9.36M$14.34M$7.20M$7.79M$4.88M$4.08M$1.95M$1.59M$1.25M
    SG&A$3.87M$4.74M$3.43M$3.91M$3.91M$4.56M$4.55M$4.64M$4.33M$4.21M$2.49M$2.24M
    Operating Income$-11,061,303$-12,674,366$-14,895,544$-13,264,534$-18,243,925$-11,759,562$-10,666,101$-4,968,796$-8,405,571$-6,152,250$-4,086,257$-24,705,766
    Interest Income$0$169,615$274,096$418,474$533,090$619,054$732,273$1.29M$961,237$426,514$50,305$39,882
    Interest Expense$3,299$2,199$0$0$0$1,452$428,748$291,068$450,052$436,936$430,135$271,307
    Income Before Tax$-10,783,194$-12,509,361$-14,441,963$-12,754,660$-17,621,472$-11,101,319$-9,746,479$-3,898,297$-7,894,745$-5,017,531$-4,419,930$-24,945,834
    Income Tax Expense$3,400$0$0$0$3,400$2,000$0$0$8,071$2,000$-982,006$291,814
    Net Income$-10,786,594$-12,509,361$-14,441,963$-12,754,660$-17,624,872$-11,103,319$-9,746,479$-3,898,297$-7,902,816$-5,019,531$-4,419,930$-24,945,834
    EBITDA$-10,779,895$-12,334,276$-14,261,954$-12,575,762$-17,434,406$-10,922,488$-9,618,101$-3,541,232$-7,414,903$-4,553,035$-3,961,424$-24,625,231
    EBITN/A$-12,507,162$-14,441,963$-12,754,660$-17,621,472$-11,099,867$-9,793,394$-3,607,229$-7,444,693$-4,580,595$-3,989,795$-24,654,020
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SKYE

    News

    Total debt per share of Skye Bioscience, Inc. – FWB:09R0

    This article provides a brief financial overview of Skye Bioscience, Inc. (FWB:09R0), specifically focusing on its total debt per share. It appears to be an excerpt from a financial data platform, indicating that the market is currently closed with no trades.

    TradingView•8/26/26•
    Neutral

    Return on assets % of Skye Bioscience, Inc. – FWB:09R0

    This article provides a financial overview of Skye Bioscience, Inc. (FWB:09R0) on the Frankfurt Stock Exchange, specifically focusing on its Return on Assets percentage. It indicates that the market is currently closed with no trades.

    TradingView•8/25/26•
    Neutral

    SKYE BIOSCIENCE INC (SKYE) Stock Forum and Discussion

    This article provides a stock forum and discussion for SKYE BIOSCIENCE INC (SKYE). It serves as a platform for investors and interested parties to discuss the company's stock performance, news, and future outlook.

    Moomoo•8/25/26•
    Neutral

    Skye Bioscience Secures Up to $22 Million ELOC and Issues $5 Million Warrant to Redmile

    Skye Bioscience has entered into a financing agreement with Redmile Biopharma Investments III, which includes an equity line of credit (ELOC) of up to $22 million and a $5 million stock warrant. The ELOC allows Skye to request monthly purchases of up to $2 million over three years, linked to the PIPE price. Additionally, Skye has granted resale registration rights for the ELOC and conversion shares to Redmile.

    TradingView•8/24/26•
    Somewhat-Bullish

    Skye Bioscience (NASDAQ: SKYE): Why Is A reverse share split taking effect in the current trading window in Focus Now?

    Skye Bioscience (NASDAQ: SKYE) is currently in focus due to a reverse share split taking effect, which presents a timely opportunity to assess the company's clinical development, exchange compliance, funding, and pipeline. This event provides a new operating reference point for investors to evaluate the company's strategy, execution, and financial flexibility. Future disclosures regarding customer activity, operating milestones, and capital discipline will be crucial in understanding the business's trajectory and resilience within the healthcare sector.

    Kalkine Media•8/24/26•
    Neutral

    Frequently Asked Questions About SKYE

    Does SKYE pay dividends?
    Skye Bioscience, Inc. Common Stock (SKYE) does not currently pay a regular dividend.
    What is SKYE's market cap?
    Skye Bioscience, Inc. Common Stock (SKYE) has a market capitalization of $7.86M with a current stock price of $1.77.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In